HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates a Buy rating on Verona Pharma (NASDAQ:VRNA) and maintains a $32 price target.
June 02, 2023 | 10:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms Buy rating on Verona Pharma and maintains a $32 price target.
The reiteration of the Buy rating and maintenance of the $32 price target by HC Wainwright & Co. analyst Raghuram Selvaraju indicates a positive outlook for Verona Pharma. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100